Increase in bacterial infections is expected to drive the growth of India Cefixime market during the forecast period.
According to TechSci Research report, “India Cefixime Market By Route of Administration (Oral v/s Intravenous), By Dose (100 mg, 200 mg, 500 mg, Others), By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule, Powder, Injection, Others), By Distribution Channel (Online v/s Offline), By Application (Urinary tract infections, Otitis media, Pharyngitis and tonsillitis, Others), By End User (Adult v/s Children), By Company, By Region, Forecast & Opportunities, FY2026”, the India cefixime market is expected to grow at a steady rate during the forecast period. Cefixime, is a third-generation cephalosporin antibiotic. Cefixime is highly stable in the presence of beta-lactamase enzymes. Cefixime is used to treat pharyngitis and tonsillitis caused by S. pyogenes. This in turn is expected to fuel the market growth through FY2026. In addition to this, uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae is also treated effectively with the use of this drug API. However, side-effects associated with drug consumption such as stomach upset/pain, diarrhea, nausea, gas, headache, or dizziness can restrict the market growth over the next few years.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “ India Cefixime Market”
https://www.techsciresearch.com/report/india-cefixime-market/7195.html
The India Cefixime market is segmented based on route of administration, dose, source, form, distribution channel, application, end user, company, and region. Based on application, the market can be fragmented into urinary tract infections, otitis media, pharyngitis and tonsillitis, others. The urinary tract infections segment is expected to dominate the market in the forthcoming years on account of rising cases of urinary tract infections caused by susceptible isolates of Escherichia coli and Proteus mirabilis. Based on source, the market can be categorized into in-house v/s contract manufacturing organizations. The in-house segment dominated the market until 2019 because in-house manufacturing helps in maintaining the quality and efficacy of the finished product as the drug is manufactured in the company’s own R&D set up. Contract manufacturing organizations segment is expected to witness significant growth in the market on account of high scalability of products coupled with substantial growth in number of contract manufacturers in the country. In terms of distribution channel, the market is split into online and offline. The offline channel is expected to dominate the market over the coming years as it is more suitable for the consumers to buy medicines from a pharmacy in the vicinity.
Covalent Laboratories Pvt. Ltd, Reva Pharma Pvt. Ltd., Orchid Pharma Ltd., Unimark Remedies Ltd., Virchow Healthcare Pvt. Ltd., Alkem Laboratories Limited, Aurobindo Pharma Limited, Taj Pharmaceuticals Ltd., Lupin Pharmaceuticals Pvt. Ltd., Dr. Reddy’s Laboratories Ltd. and others are some of the leading players operating in India cefixime market. Companies operating in the market are using strategies such as product launches, mergers, and collaborations, customer focused approach to boost their share and increase their geographic reach.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7195
Customers can also request for 10% free customization on this report.
“India cefixime market is expected to witness growth during the forecast period as it is used to treat uncomplicated urinary tract infections. Also, Cefixime is defined as a broad spectrum cephalosporin antibiotic which is used for treating bacterial infections of the ear. This is further expected to create lucrative opportunities for the market growth of India Cefixime market over the next five years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.
“India Cefixime Market By Route of Administration (Oral v/s Intravenous), By Dose (100 mg, 200 mg, 500 mg, Others), By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule, Powder, Injection, Others), By Distribution Channel (Online v/s Offline), By Application (Urinary tract infections, Otitis media, Pharyngitis and tonsillitis, Others), By End User (Adult v/s Children), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India cefixime market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India cefixime market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
